ALZAI Health

ALZAI delivers AI-driven Alzheimer's Disease risk assessment completely non-invasively, using only pre-existing data found in every patient record.

HealthTech
public
Toronto, Canada Founded 2024
Website ↗
Last updated 2026-08-22
Total raised
$3.0M
Stage
Founded
2024
Headcount
HQ
Toronto, Canada
Sector
HealthTech

About

ALZAI Health Corp. is a healthcare technology company developing non-invasive, artificial intelligence-driven disease risk identification solutions using routine healthcare data. Its proprietary platform identifies individuals at elevated risk for disease before clinical diagnosis, enabling earlier intervention opportunities and supporting improved patient outcomes. ALZAI's technology has been validated on large-scale healthcare datasets and is designed for integration into existing healthcare infrastructure, including electronic medical record systems, cloud-based environments, and enterprise healthcare platforms. The company's mission is to address a critical gap in the fight against Alzheimer's Disease by delivering effective risk screening for better detection, earlier treatment, and effective prevention. ALZAI also secured an exclusive global license for AI-driven liver disease risk identification technology, expanding its platform beyond Alzheimer's disease.

Funding history · 1 round · $3.0M total

2026-06
IPO $3.0M
★ Haywood Securities Inc.

Q&A

What is ALZAI Health's primary focus?
ALZAI Health focuses on developing non-invasive, AI-driven disease risk identification solutions using routine healthcare data, primarily for Alzheimer's Disease.
When was ALZAI Health founded?
ALZAI Health was founded in 2024.
What is ALZAI Health's primary sector?
ALZAI Health's primary sector is HealthTech.
Where is ALZAI Health headquartered?
ALZAI Health is headquartered in Toronto, Canada.
What is ALZAI Health's mission regarding Alzheimer's Disease?
ALZAI Health's mission is to address a critical gap in the fight against Alzheimer's Disease by delivering effective risk screening for better detection, earlier treatment, and effective prevention.
What other disease area has ALZAI Health expanded into?
ALZAI Health has secured an exclusive global license for AI-driven liver disease risk identification technology, expanding its platform beyond Alzheimer's disease.
Who are the co-founders of ALZAI Health?
The co-founders of ALZAI Health are Hayim Raclaw (CEO), Roy Kait (CRO), Dr. Amir Glik (CMO), and Ofri Kait (Director Business Development & Operations).
When did ALZAI Health conduct an IPO and how much capital was raised?
In June 2026, ALZAI Health conducted an IPO, raising $2,956,500. Haywood Securities Inc. was a lead investor in this round.

Team · 5

Hayim Raclaw
Founder · Director, Chief Executive Officer & Co-founder
Roy Kait
Founder · Director, Chief Revenue Officer & Co-founder
Dr. Amir Glik, MD
Founder · Director, Chief Medical Officer & Co-founder
Ofri Kait
Founder · Director Business Development & Operations & Co-Founder
Israel Messer
Chief Financial Officer

Sectors & technology

Primary sector
HealthTech
Technologies
Target customers
Business model
LicensingProfessional ServicesPay-per-screenAnnual Licensing
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitealzaihealth.com

Identifiers & details

Legal nameALZAI Health Corp.
Founded2024